EN DE
Watch Shanghai Junshi Biosciences Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Shanghai Junshi Biosciences Co Ltd (1877) fair value: what the stock is really worth

As of Oct 29, 2026: fair value (intrinsic value) of Shanghai Junshi Biosciences Co Ltd stock HK$4.21, price HK$15.88, upside -73.5%, quality 40 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Home China · ISIN CNE100003FF7

SJ Shanghai Junshi Biosciences Co Ltd logo Thin data Oct 29, 2026

Shanghai Junshi Biosciences Co Ltd

1877 · HK
Very expensive, weak quality

Our calculation puts a fair price 73% below what the stock costs today.

Low debt
Revenue last quarter +45% vs. a year ago.
Quality 40/100
Expensive Growth (revenue 5y +8.8 %/yr in CNY)
Fair value HK$4.21 · Strongly overvalued (−73.5%)
Loss-making · -14.6% net margin (TTM)
Negative free cash flow
Trails peers (4/11)
Narrow moat 12/100
Thin data
Watch Shanghai Junshi Biosciences Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$70.40 HK$9.24 Fair Value HK$4.21 Jun 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.

How to read this chart

60‑month range HK$9.24 – HK$70.40 · fair‑value band HK$3.14 – HK$6.28 · the HK$15.88 price screens above the HK$4.21 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.

Follow Shanghai Junshi Biosciences Co in your weekly email

Every Wednesday you see whether Shanghai Junshi Biosciences Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China.

Show moreShow less

The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer.

It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in phase I/II clinical trial to treat NSCLC; JS110, a small molecule inhibitor of the nuclear export protein XPO1 which is in phase I/II clinical trial to treat endometrial cancer; JS007, a recombinant humanized anti-Cytotoxic T lymphocyte associated antigen-4 monoclonal antibody which is in phase I/II clinical trial to treat lung cancer and melanoma; and JT002, A small nucleic acid immunomodulator which is in phase I/II clinical trial for the treatment of seasonal allergic rhinitis.

In addition, the company offers TUOYI/LOQTORZI/ZYTORVI for tumors; JUNMAIKANG for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, Crohn's disease, uveitis, polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease; VV116/JT001, an oral nucleoside analog drug; and JUNSHIDA to treat hyperlipidemia.

The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

Stock analysis

Shanghai Junshi Biosciences Co Ltd (1877) currently trades at HK$15.88, while our model-based Fair Value estimate is HK$4.21, 73.5% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the data coverage at low.

Scenario range: HK$3.14 (bear) to HK$6.28 (bull), the price of HK$15.88 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Shanghai Junshi Biosciences Co Ltd reported revenue of 2.4B CNY in FY2025 versus 4.0B CNY in FY2021, a compound −11.8%/yr. Reported net income was −852M CNY in FY2025.

Key figures

Market cap HK$16.3B (≈ $2.1B) Mid · P/S ratio 5.42 · EPS (TTM) HK$−0.4540 · Dividend yield 0.5% · Net margin −14.6% · Return on equity −9.3% · Return on assets (EBIT) −13.7% · Operating margin −5.3%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 45% below its 52-week high and 3% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −73%, 1877 screens richer than that median.

Fair Value models

Bear HK$3.14 Fair Value HK$4.21 Bull HK$6.28
Price HK$15.88 · Upside -73.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) HK$3.14 HK$4.21 HK$6.28 54
All 1 models by family
Asset-Based
NCAV (Graham) HK$3.14 HK$4.21 HK$6.28 54

Open the full fair value analysis →

Quality Score breakdown

Overall quality 40/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 85
Are margins and returns getting better?
Cashflow 1
Do the profits arrive as real cash?
Financial strength 52
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 56
How calm the share price moves, does not count
Momentum 12
Price trend of the last 3 to 12 months, does not count
Near the 52-week high 2
Distance to the 52-week high, does not count
New shares 64
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 26/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+24.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.8%
Start year 2020 (pandemic). Over 10 years: +96.1% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+73.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−104.6% (2020) → −37.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

1877 screens overvalued: fair value 73% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Shanghai Junshi Biosciences Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 598 stocks

Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 40 · Below median
Fair Value upside −73.5% · Bottom 25%
Profitability
Return on assets −6.9% · Above median
Net margin (12 months) −14.6% · Below median
Operating margin (12 months) −5.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 45.2% · Top 25%
Dividend yield (12 months) 0.5% · Below median
Balance sheet
Debt / equity 0.46× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.29× · Pricier than median
P/S (12 months) 4.56× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)77 · sector 97
DIVIDEND (yield)11 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $816.10 $1,275 +56% vs 1877
Vertex Pharmaceuticals Incorporated VRTX $517.49 $569.24 +10% vs 1877
Samsung Biologics Co 207940 1,374,000 KRW 1,511,400 KRW +10% vs 1877
Alnylam Pharmaceuticals, Inc ALNY $174.00 $191.40 +10% vs 1877
WuXi Biologics (Cayman) Inc 2269 HK$45.80 HK$50.38 +10% vs 1877
argenx SE ARGX $882.48 $908.40 +3% vs 1877
CSL Limited CSL A$196.78 A$178.75 −9% vs 1877
BeOne Medicines AG 6160 HK$217.60 HK$153.56 −29% vs 1877
Celltrion, Inc 068270 188,600 KRW 74,944 KRW −60% vs 1877
Royalty Pharma plc RPRX $64.76 $19.01 −71% vs 1877

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Shanghai Junshi Biosciences Co Ltd · Fair Value
HK$4.21 −73%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Shanghai Junshi Biosciences Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/1877

Frequently asked questions

Is Shanghai Junshi Biosciences Co Ltd (1877) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of HK$4.21 versus a price of HK$15.88, about −73% upside (overvalued).
What is the fair value of 1877?
Our model-based fair value for Shanghai Junshi Biosciences Co Ltd is HK$4.21 (as of Oct 29, 2026), built from audited fundamentals. The current price: HK$15.88.
What is the quality score of 1877?
Shanghai Junshi Biosciences Co Ltd has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Shanghai Junshi Biosciences Co Ltd (1877)?
Our model-based price target is the fair value of HK$4.21 (as of Oct 29, 2026) from 1 valuation models. Cautious scenario HK$3.14, optimistic scenario HK$6.28. It is a calculation from audited fundamentals, not an analyst target.
What is the Shanghai Junshi Biosciences Co Ltd stock forecast for 2026?
Our models put fair value at HK$4.21, about −73% upside versus a price of HK$15.88 (overvalued). Cautious scenario HK$3.14, optimistic scenario HK$6.28. The calculation is refreshed regularly with new filings.
What is the revenue of Shanghai Junshi Biosciences Co Ltd (1877)?
Shanghai Junshi Biosciences Co Ltd reported trailing-twelve-month revenue of about 3.0B CNY (latest available figure, as of Oct 29, 2026).
Does Shanghai Junshi Biosciences Co Ltd pay a dividend?
Shanghai Junshi Biosciences Co Ltd currently shows a dividend yield of 0.53% relative to its recent price (as of Oct 29, 2026).
What is the intrinsic value of Shanghai Junshi Biosciences Co Ltd (1877)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Shanghai Junshi Biosciences Co Ltd it is HK$4.21 per share (as of Oct 29, 2026), against a price of HK$15.88. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Shanghai Junshi Biosciences Co Ltd stock overvalued or undervalued in 2026?
As of Oct 29, 2026, 1877 trades above its calculated fair value: price HK$15.88, fair value HK$4.21, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 1877?
No. The price is what the market pays today (HK$15.88); the fair value is what the company's own numbers justify (HK$4.21). For Shanghai Junshi Biosciences Co Ltd the two are HK$11.67 per share apart. That gap is exactly why we show both numbers side by side.
How much is Shanghai Junshi Biosciences Co Ltd worth?
The market values Shanghai Junshi Biosciences Co Ltd at about HK$16.3B (market capitalisation, as of Oct 29, 2026). Per share that is HK$15.88; our models calculate a fair value of HK$4.21 per share.
What do the bullish and bearish scenarios say about 1877?
Our models span a range for Shanghai Junshi Biosciences Co Ltd: cautious scenario HK$3.14, base HK$4.21, optimistic HK$6.28 per share (as of Oct 29, 2026, price HK$15.88). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Shanghai Junshi Biosciences Co Ltd (1877)?
Balance-sheet figures for Shanghai Junshi Biosciences Co Ltd (as of Oct 29, 2026): return on equity −9.3%, debt of 0.46 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 1877 from its 52-week high?
Shanghai Junshi Biosciences Co Ltd trades at HK$15.88, about 45% below its 52-week high of HK$28.96 and 3% above the low of HK$15.37 (as of Oct 29, 2026). Distance from the high says nothing about value: that is what the fair value of HK$4.21 is for.
Which stocks are comparable to Shanghai Junshi Biosciences Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Shanghai Junshi Biosciences Co Ltd stock attractive at the current price?
The data as of Oct 29, 2026: price HK$15.88, calculated fair value HK$4.21 (−73%), Quality Score 40/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 1877 calculated?
We run Shanghai Junshi Biosciences Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of HK$4.21, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.1 % above its aggregate fair value. Shanghai Junshi Biosciences Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Shanghai Junshi Biosciences Co Ltd (1877)?
The closing price on Oct 29, 2026 was HK$15.88. Our model-based fair value is HK$4.21, about −73% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Shanghai Junshi Biosciences Co Ltd right now?
The price sits above even our optimistic bull case (HK$6.28). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (HK$3.14 to HK$6.28) leaves room in how you read the outcome.

Key figures of Shanghai Junshi Biosciences Co Ltd

How large is the market capitalisation of Shanghai Junshi Biosciences Co Ltd (1877)?
The market capitalisation of Shanghai Junshi Biosciences Co Ltd is HK$16.3B (≈ $2.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Shanghai Junshi Biosciences Co Ltd (1877)?
The price-to-sales ratio of Shanghai Junshi Biosciences Co Ltd is 5.42 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Shanghai Junshi Biosciences Co Ltd (1877)?
Earnings per share at Shanghai Junshi Biosciences Co Ltd are HK$−0.4540. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Shanghai Junshi Biosciences Co Ltd (1877)?
The dividend yield of Shanghai Junshi Biosciences Co Ltd is 0.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Shanghai Junshi Biosciences Co Ltd (1877)?
The net margin of Shanghai Junshi Biosciences Co Ltd is −14.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Shanghai Junshi Biosciences Co Ltd (1877)?
The return on equity (ROE) of Shanghai Junshi Biosciences Co Ltd is −9.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Shanghai Junshi Biosciences Co Ltd (1877)?
On an EBIT basis the return on assets of Shanghai Junshi Biosciences Co Ltd is −13.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Shanghai Junshi Biosciences Co Ltd (1877)?
The operating margin of Shanghai Junshi Biosciences Co Ltd is −5.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Shanghai Junshi Biosciences Co Ltd (1877)?
Revenue at Shanghai Junshi Biosciences Co Ltd is growing +45.2% versus a year earlier (3y avg +18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Shanghai Junshi Biosciences Co Ltd (1877) generate?
The free cash flow of Shanghai Junshi Biosciences Co Ltd is −1.2B CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Shanghai Junshi Biosciences Co Ltd (1877) carry?
The net debt of Shanghai Junshi Biosciences Co Ltd is 1.5B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Shanghai Junshi Biosciences Co Ltd in the live analysis

One click puts Shanghai Junshi Biosciences Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.